Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Combined tenofovir, lamivudine, and dolutegravir treatment increases leptin and FABP4 expression in human subcutaneous adipose tissue.

Zanardo LW., Izabel LDS., Hamada LM., Carvalho MB., Silva PAGOE., Joaquim HDG.

Prospective Study on Systemic / IV, published in Einstein (Sao Paulo) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Einstein (Sao Paulo) (2026)
Country
Brazil
Reported sample size
—
Source database
PubMed
PMID
41711779
PMCID
PMC12977281
DOI
10.31744/einstein_journal/2026AO1770

Abstract (original English)

Introduction Several antiretroviral regimens reportedly affect adipose tissue function. While earlier antiretroviral combinations were associated with lipodystrophy, more recent regimens, particularly those containing dolutegravir, have been linked to fat gain. However, the direct impact of contemporary antiretroviral regimens on human adipose tissue remains unclear. Objective Therefore, this study aimed to elucidate the effects of the combination of TDF, 3TC, and DTG on human adipose tissue function in vitro. For comparison, we also analyzed an alternative regimen consisting of AZT, 3TC, and DTG, given the well-documented association of AZT with lipodystrophy. Methods Cells from the stromal vascular fraction of both adipose depots were isolated and treated with each antiretroviral combination for 72 hours. Additionally, adipose tissue explants were treated with each regimen for one week in vitro. Results Both treatments significantly reduced the number of viable stromal vascular fraction cells, as determined by the MTT assay. Moreover, combined TDF, 3TC, and DTG treatment increased FABP4 and leptin expression only in subcutaneous adipose tissue. No significant changes were observed in inflammatory cytokine expression, adiponectin expression and secretion, or lipolysis in either adipose depot treated with the antiretroviral combinations. Conclusion These findings suggest that t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansOxazinesDolutegravirSubcutaneous FatPiperazinesLamivudineFatty Acid-Binding ProteinsLeptinPyridonesHeterocyclic Compounds, 3-Ring

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research